The unattainable criteria for new infant vaccines
Background. In 2013, the US Advisory Committee on Immunization Practices (ACIP) opted against adding meningococcal vaccines to the infant schedule due to poor cost-effectiveness. This raises a policy question: if meningococcal disease is too rare to justify routine vaccination, are there other vacci...
Main Authors: | Christopher J. Gill, Lauren Hodsdon, Mathuram Santosham, Katherine L. O'Brien |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-05-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2017.1328334 |
Similar Items
-
Disparities in healthcare providers’ interpretations and implementations of ACIP’s meningococcal vaccine recommendations
by: Liping Huang, et al.
Published: (2020-04-01) -
Why the American Academy of Pediatrics recommends initiating HPV vaccine at age 9
by: Sean T. O’Leary
Published: (2022-11-01) -
Primary immunization of meningococcal meningitis vaccine among children in Hangzhou, China, 2008–2017
by: Xinren Che, et al.
Published: (2021-04-01) -
Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers
by: Miguel Tregnaghi, et al.
Published: (2014-09-01) -
Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
by: Samba O. Sow, et al.
Published: (2023-08-01)